Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
Pharming Group N.V. today announced 2026 financial guidance and will highlight its advancing clinical-stage rare disease pipeline, including two major value-creating programs, at a virtual Investor Day taking place later today.
- Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease
- Introduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program
- 2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)
- 2026 total operating expense guidance of US$330 – US$335 million
- Investor Day will be webcast today starting at 10:00 am EST (16:00 CET)
Click here to register and view live event
A replay will be available on our website shortly after the conclusion of the event.
The Investor Day will focus on the scientific rationale, clinical strategy, and long‑term opportunity underpinning Pharming’s pipeline programs in primary immunodeficiencies (PIDs) with immune dysregulation and mitochondrial DNA (mtDNA)‑driven mitochondrial disease.
Fabrice Chouraqui, Chief Executive Officer of Pharming, commented:
“Pharming’s vision of developing into a leading global rare disease company is grounded in the strength of our two commercial products and our high-value pipeline. We expect our commercial portfolio to continue delivering robust growth, with total revenues between US$405 million and US$425 million in 2026. We are excited to showcase the breadth and quality of our pipeline at today’s Investor Day. Leniolisib and napazimone (KL1333) are being developed for large, underserved rare disease populations with significant unmet need, and are supported by a strong and growing body of biological and clinical evidence. We believe both programs offer substantial long‑term value‑creating potential for Pharming.”